title: Why do we need multifunctional neuroprotective and neurorestorative drugs for Parkinson's and Alzheimer's disorders?
abstract: Parkinson's disease (PD) and Alzheimer's disease (AD) are severe neurodegenerative disorders, with no drugs that are currently approved to prevent the neuronal cell loss characteristic in brains of patients suffering from PD and AD, and all drug treatments are symptomatic and monomodal in their action. Due to the complex pathophysiology, including a cascade of neurotoxic molecular events that result in neuronal death and predisposition to depression and eventual dementia, and etiology of these disorders, an innovative approach towards neuroprotection or neurorestoration (neurorescue) is the development and use of multifunctional pharmaceuticals which can act at different brain regions and neurons. Such drugs target an array of pathological pathways, each of which is believed to contribute to the cascades that ultimately lead to neuronal cell death. In this short review, we discuss examples of novel multifunctional ligands that may have potential as neuroprotective-neurorestorative therapeutics in PD and AD, some of which are under development. The compounds discussed originate from synthetic chemistry as well as from natural sources.
authors.affiliation: Eve Topf and US National Parkinson Foundation Centers of Excellence for Neurodegenerative Diseases, The Bruce Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel, and Department of Biology, Yonsei University, Seoul, Korea.
authors.forename: Moussa B H
authors.initials: MB
authors.lastname: Youdim
keywords: Alzheimer’s disease; Parkinson’s disease; Rasagiline multimodal drugs; antiapoptotic; neuroprotection; neurorestoration
references.citation: Drugs Aging. 1998 Jun;12(6):495-514
references.pmid: 9638397
references.citation: Eur J Pharmacol. 2002 Sep 13;451(2):157-60
references.pmid: 12231385
references.citation: Physiol Rev. 1999 Oct;79(4):1431-568
references.pmid: 10508238
references.citation: Nat Neurosci. 2002 Nov;5 Suppl:1039-42
references.pmid: 12403981
references.citation: Can J Neurol Sci. 1987 Aug;14(3 Suppl):407-13
references.pmid: 3315146
references.citation: Eur J Pharmacol. 2003 Jan 1;458(1-2):73-9
references.pmid: 12498909
references.citation: Curr Treat Options Cardiovasc Med. 2003 Dec;5(6):441-449
references.pmid: 14575621
references.citation: Stroke. 2003 Sep;34(9):2234-9
references.pmid: 12920258
references.citation: J Mol Neurosci. 2003;20(3):267-75
references.pmid: 14501007
references.citation: J Neurosci. 2005 Sep 21;25(38):8807-14
references.pmid: 16177050
references.citation: Haemostasis. 1998 May-Aug;28(3-4):124-33
references.pmid: 10420060
references.citation: J Med Chem. 2005 Oct 20;48(21):6523-43
references.pmid: 16220969
references.citation: Biochem Pharmacol. 1993 Jan 7;45(1):13-9
references.pmid: 8424806
references.citation: FASEB J. 2007 Dec;21(14):3835-44
references.pmid: 17690154
references.citation: J Neurochem. 2003 Jul;86(2):290-7
references.pmid: 12871570
references.citation: Neurobiol Aging. 1997 Sep-Oct;18(5):497-507
references.pmid: 9390776
references.citation: Neurotox Res. 2010 Jan;17(1):15-27
references.pmid: 19609632
references.citation: Neurotoxicology. 2004 Jan;25(1-2):271-7
references.pmid: 14697902
references.citation: Acta Neurochir (Wien). 2000;142(11):1287-92
references.pmid: 11201645
references.citation: Bioorg Med Chem. 2007 Feb 1;15(3):1525-32
references.pmid: 17157509
references.citation: Drug Discov Today. 2007 Jan;12(1-2):34-42
references.pmid: 17198971
references.citation: FASEB J. 2009 Nov;23(11):3766-79
references.pmid: 19638399
references.citation: J Med Chem. 2009 Jul 23;52(14):4095-8
references.pmid: 19485411
references.citation: Neurosignals. 2005;14(1-2):46-60
references.pmid: 15956814
references.citation: Neurotherapeutics. 2009 Jan;6(1):1-3
references.pmid: 19110194
references.citation: J Neural Transm (Vienna). 2005 Apr;112(4):519-37
references.pmid: 15666041
references.citation: J Neurochem. 2005 Oct;95(1):79-88
references.pmid: 16181414
references.citation: Curr Atheroscler Rep. 2001 Jul;3(4):334-9
references.pmid: 11389800
references.citation: FASEB J. 2003 May;17(8):952-4
references.pmid: 12670874
references.citation: Mol Nutr Food Res. 2006 Feb;50(2):229-34
references.pmid: 16470637
references.citation: Drugs Today (Barc). 2005 Jun;41(6):369-91
references.pmid: 16110345
references.citation: Br J Pharmacol. 2003 Apr;138(7):1207-9
references.pmid: 12711619
references.citation: CNS Drug Rev. 2003 Fall;9(3):275-308
references.pmid: 14530799
references.citation: Biochem Pharmacol. 1997 Nov 1;54(9):973-8
references.pmid: 9374417
references.citation: CNS Drugs. 2003;17(10):729-62
references.pmid: 12873156
references.citation: ACS Chem Biol. 2010 Jun 18;5(6):603-10
references.pmid: 20455574
references.citation: FASEB J. 2005 Nov;19(13):1899-901
references.pmid: 16148027
references.citation: Pharmacoeconomics. 2005;23(2):193-206
references.pmid: 15748093
references.citation: Neurosci Lett. 2005 Jul 22-29;383(1-2):49-53
references.pmid: 15936510
references.citation: Neurobiol Aging. 1994 Jul-Aug;15(4):399-408
references.pmid: 7969716
references.citation: Trends Pharmacol Sci. 2004 Mar;25(3):124-9
references.pmid: 15019266
references.citation: Ann Neurol. 2003;53 Suppl 3:S87-97; discussion S97-9
references.pmid: 12666101
references.citation: Mech Ageing Dev. 2005 Feb;126(2):317-26
references.pmid: 15621213
references.citation: J Biol Chem. 2002 Sep 27;277(39):36040-4
references.pmid: 12130655
references.citation: Bioorg Med Chem. 2005 Feb 1;13(3):773-83
references.pmid: 15653345
references.citation: Bioorg Med Chem. 2004 Apr 1;12(7):1799-806
references.pmid: 15028270
references.citation: J Neurochem. 2005 Jun;93(5):1157-67
references.pmid: 15934936
references.citation: J Neurosci Res. 2005 Jan 1-15;79(1-2):172-9
references.pmid: 15573406
references.citation: J Nutr Biochem. 2004 Sep;15(9):506-16
references.pmid: 15350981
references.citation: Nat Rev Neurosci. 2002 Dec;3(12):932-42
references.pmid: 12461550
references.citation: Neurotox Res. 2006 Dec;10(3-4):181-92
references.pmid: 17197368
references.citation: N Engl J Med. 1998 Oct 8;339(15):1044-53
references.pmid: 9761807
references.citation: Nat Rev Drug Discov. 2005 Aug;4(8):625-6
references.pmid: 16106586
references.citation: Prog Neurobiol. 2007 Aug;82(6):348-60
references.pmid: 17659826
references.citation: Neurology. 2003 Dec 9;61(11 Suppl 6):S62-8
references.pmid: 14663013
references.citation: Can J Neurol Sci. 1987 Aug;14(3):303-5
references.pmid: 3664372
references.citation: Trends Pharmacol Sci. 2003 Aug;24(8):402-8
references.pmid: 12915049
references.citation: Biochim Biophys Acta. 1996 Dec 13;1304(3):210-22
references.pmid: 8982267
references.citation: Curr Drug Targets. 2004 Aug;5(6):535-51
references.pmid: 15270200
references.citation: FASEB J. 2008 May;22(5):1296-305
references.pmid: 18048580
references.citation: Nat Rev Neurosci. 2004 Nov;5(11):863-73
references.pmid: 15496864
references.citation: J Med Chem. 2002 Nov 21;45(24):5260-79
references.pmid: 12431053
references.citation: N Engl J Med. 1998 Oct 15;339(16):1130-43
references.pmid: 9770561
references.citation: Eur J Neurol. 2002 Jul;9(4):377-82
references.pmid: 12099922
references.citation: Toxicol Appl Pharmacol. 2002 Jun 1;181(2):89-92
references.pmid: 12051992
references.citation: Brain Res. 1996 Dec 2;742(1-2):80-8
references.pmid: 9117424
references.citation: J Neurochem. 2005 Oct;95(1):68-78
references.pmid: 16181413
references.citation: J Clin Psychiatry. 2002 Mar;63(3):225-31
references.pmid: 11926722
references.citation: Clin Neuropharmacol. 1998 May-Jun;21(3):141-51
references.pmid: 9617505
references.citation: Nature. 1998 Apr 9;392(6676):605-8
references.pmid: 9560156
references.citation: Expert Opin Investig Drugs. 2006 Aug;15(8):873-86
references.pmid: 16859391
references.citation: Brain Res. 2005 Feb 9;1034(1-2):11-24
references.pmid: 15713255
references.citation: J Neurochem. 2007 Jan;100(2):490-502
references.pmid: 17144902
references.citation: Biosci Biotechnol Biochem. 2001 Jan;65(1):126-32
references.pmid: 11272815
references.citation: Neurochem Res. 2006 Mar;31(3):395-9
references.pmid: 16733815
references.citation: Drugs Aging. 1999 May;14(5):359-73
references.pmid: 10408736
references.citation: Trends Pharmacol Sci. 2004 May;25(5):249-53
references.pmid: 15120490
references.citation: Methods Enzymol. 2001;335:190-203
references.pmid: 11400368
references.citation: Am J Clin Nutr. 2005 Jan;81(1 Suppl):313S-316S
references.pmid: 15640496
references.citation: Neurobiology (Bp). 2000;8(1):47-54
references.pmid: 11008877
references.citation: Neuropharmacology. 1999 Jun;38(6):735-67
references.pmid: 10465680
references.citation: Pharmacol Res Commun. 1986 May;18(5):407-17
references.pmid: 3737654
references.citation: Life Sci. 1988;43(24):2049-57
references.pmid: 2850421
references.citation: J Neurochem. 2006 Apr;97(2):527-36
references.pmid: 16539659
references.citation: Trends Pharmacol Sci. 2005 Jan;26(1):27-35
references.pmid: 15629202
references.citation: Psychopharmacology (Berl). 2002 Mar;160(3):318-24
references.pmid: 11889501
references.citation: J Pharmacol Exp Ther. 1995 Jan;272(1):177-83
references.pmid: 7815331
references.citation: Neurobiol Aging. 2005 Jun;26(6):957-64
references.pmid: 15718055
references.citation: Bioorg Med Chem. 2003 Apr 3;11(7):1299-310
references.pmid: 12628657
references.citation: Parkinsonism Relat Disord. 2000 Jan;6(1):25-47
references.pmid: 18591148
references.citation: N Engl J Med. 2009 Sep 24;361(13):1268-78
references.pmid: 19776408
references.citation: FASEB J. 2004 Sep;18(12):1471-3
references.pmid: 15247150
references.citation: Cochrane Database Syst Rev. 2000;(2):CD001928
references.pmid: 10796454
references.citation: Drug Discov Today. 2004 Aug 1;9(15):641-51
references.pmid: 15279847